RT Journal Article
SR Electronic
T1 Retinol Depletion in Severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.30.21250844
DO 10.1101/2021.01.30.21250844
A1 Aziz Rodan Sarohan
A1 Hakan Akelma
A1 Eşref Araç
A1 Özgür Aslan
YR 2021
UL http://medrxiv.org/content/early/2021/02/01/2021.01.30.21250844.abstract
AB Background and Purpose Vitamin A is depleted during infections. Vitamin A has been used successfully in measles, RSV and AIDS patients and is an effective vaccine adjuvant. In this study, low retinol levels were found in patients with severe COVID-19. Retinoid signaling impairment in COVID-19 disrupts Type-I interferon synthesis.Material and Method Two groups were formed in the study. The patient group consisted of 27 (Group 1) severe COVID-19 patients hospitalized in the intensive care unit with respiratory failure, and the control group consisted of 23 (Group 2) patients without COVID-19 symptoms. Serum retinol levels were analyzed by ELIZA and HPLC in both groups.Findings Retinol levels were found to be significantly lower in the patient group (P <0.001). There was no difference in retinol between two different age groups in the patient group (P> 0.05). There was no significant difference in retinol between men and women (P> 0.05). Comorbidity did not affect serum retinol levels (P >0.05).Conclusion Serum retinol levels were low in patients with severe COVID-19. Drugs preventing retinol excretion were not stopped in the patient group. Some patients took vitamin A externally. Despite this, retinol was low in COVID-19 patients. Retinol depletion impairs Type-I interferon synthesis by impairing retinoid signaling. Retinoid signaling may be the main pathogenetic disorder in COVID-19. This pathogenesis can serve as a guide for adjuvants, drug targets, and candidate drugs. Retinol, retinoic acid derivatives, and some CYP450 inhibitors may work on COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding or similar incentives were received for any phase of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with the approval of the ethics committee and the approval of Diyarbakır Gazi Yasargil Training and Research Hospital, University of Health Sciences, and the approval of the Ministry of Health dated 03.06.2020 and numbered T22_10_40.xml. All protocols were implemented within the recommendations of the local ethics committee. All subjects were included in the study following the protocols approved by the local ethics committee. When the patients were hospitalized, they were informed about the study and were included in the study after obtaining their consent for signature. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sources referenced in the study are cited appropriately in the text and in the series of sources. This article can be used provided that the authors are properly cited. Article content cannot be used for commercial purposes without the consent of the responsible author.